Market capitalization | JPY6.55t |
Enterprise Value | JPY11.55t |
PER (TTM) P/E ratio | 45.21 |
EV/FCF (TTM) EV/FCF | 24.85 |
EV/Sales (TTM) EV/Sales | 2.71 |
P/S ratio (TTM) P/S ratio | 1.54 |
P/B ratio (TTM) P/B ratio | 0.90 |
Dividend yield | 4.70% |
Last dividend (FY25) | JPY196.00 |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
16 Analysts have issued a Takeda Pharmaceutical forecast:
16 Analysts have issued a Takeda Pharmaceutical forecast:
Mar '24 |
+/-
%
|
||
Turnover | 4,263,762 4,263,762 |
6%
6%
|
|
Gross income | 2,199,809 2,199,809 |
2%
2%
|
|
EBITDA | 1,200,404 1,200,404 |
6%
6%
|
EBIT (operating result) EBIT | 414,856 414,856 |
32%
32%
|
Net profit | 144,067 144,067 |
55%
55%
|
Figures in millions JPY.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Head office | Japan |
CEO | Christophe Weber |
Employees | 49,281 |
Founded | 1781 |
Website | www.takeda.co.jp |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.